Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
Globe Newswire•17/11/2026•18:40 ET
0
Key Highlights
- ➤BMS will sponsor a Phase 1/2 trial of ERAS-0015 with navlimetostat
- ➤Erasca will supply ERAS-0015 for MTAP-deleted pancreatic cancer study
- ➤BMS and Erasca retain rights to their respective compounds under the agreement
- ➤ERAS-0015 showed confirmed partial responses at doses as low as 8 mg once daily
Expert Statements
Jonathan E. Lim, Chairman, CEO, and co-founder of Erasca
“The early clinical activity demonstrated by ERAS-0015 has been encouraging, and we are excited to collaborate with BMS to further explore its potential in combination with navlimetostat, a clinical-stage investigational molecule with a compelling clinical profile.”
Jonathan E. Lim, Chairman, CEO, and co-founder of Erasca
“By bringing together complementary mechanisms with strong scientific rationale, this combination expands the potential of ERAS-0015 as a backbone of choice across RASm cancers and reinforces our strategy of pairing it with promising agents that may increase patient benefit. We look forward to working with BMS to advance this combination for patients with pancreatic cancer.”
ERAS-0015 will be evaluated with PRMT5 inhibitor navlimetostat in MTAP-deleted pancreatic cancer in Phase 1/2 trial
BMS will sponsor the clinical trial and Erasca will supply ERAS-0015
Get started
Create a free account to read the full story.
